The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Rotten Robbie is a TROLL...... AND A SHORTER PLEASE IGNORE HIM..HE IS TROUBLE...........................................................
Who's guessing rottenrobbie is a paid troll. A quick look over his past posts on vast and odx makes me believe so lol
I don't think you are thining that through... it's all about rpc and not lab tests...
Lab tests will help, it's a war on the virus... but rpc tests are what is needed to re-openign the world economies..
The UK goverment need something to paper over their cracks... this doesnt I'm afraid as they have failed us.
Patience is needed... don't sell and chase the 20 % ... you'll be kicking yourself.... kicking
"I think you'll find this wont do us ODX holder any favours, bad news for us Im afraid."
It's a lab-based, professional used ELISA antibody test. Frankly, it's old tech (we've had one for months) that will take up scarce lab capacity needed for antigen testing. LFT is the future for antibody testing.
their massive order was for antigen tests
they have only announced that they now have a ce marked antibody test with 3 million/month manufacturing capacity - no sales claimed yet. ODX still well in the game on that front.
So NCYT just got £250m order. I should gave held the shares I had there.
But moonshot is £100bn, supposed. So plenty of space for others. If anything, they have been clear it is home based rapid testing that unlocks us.
Keep the faith, stay patient. Its hard!
UNVRKW,
why no RNS to confirm these orders, these are price sensitive pieces of information at this stage.
Kip , nonsense there test is ce marked only , hospital based . Keep up omega antibody tests are ahead of this by months
Odx have an Elisa based lab antibody test also available and being sold. Been out there sometime.
Mizman,
you know this how?
Thanks
No, it's selling right now at £13 and we will get RNS by Wednesday confirming that.
It does have one advantage over our test - it exists and ours doesn't.
It's lab based. No competition tion to our home test.
Paris, France and Camberley, UK - 29 September 2020 - Novacyt, an international specialist in clinical diagnostics, announces that, further to the announcement on 27 July 2020, the Company has launched a CE-Mark approved serology (antibody) 96-well plate ELISA (enzyme-linked immunosorbent assay) test for the detection of IgG antibodies to SARS-CoV-2 derived from plasma and serum samples.
The test has been launched by Microgen Bioproducts Limited (Microgen), which is part of Novacyt's protein diagnostics division Lab21. The new antibody test complements Novacyt's existing COVID-19 product portfolio, in particular the Company's polymerase chain reaction (PCR) test for COVID-19, to provide clinicians with the diagnostic tools to detect and differentiate between active and prior SARS-CoV-2 infections in patients.
The new antibody test has been validated in a study where 1,673 patient samples (112 positive samples and 1,561 negative samples) were evaluated. The test demonstrated 100% sensitivity in patients that were tested at 14 days after testing positive for COVID-19 by a PCR test. The antibody test also demonstrated 99.4% specificity.
The ELISA test has been designed for use in all established central laboratories and follows a standard ELISA protocol that makes it compatible with most 96-well plate automation systems. Novacyt has sufficient manufacturing capacity to deliver more than three million antibody tests per month initially and the Company is working with its manufacturing partner to ensure this can be increased depending on demand.
Graham Mullis, Chief Executive Officer of Novacyt, commented:
"Novacyt remains committed to supporting the global response to COVID-19 through the delivery of high performance diagnostics. We continue to strengthen our product offering in COVID-19 testing as demand continues and we are delighted to launch an antibody test. We believe an antibody test plays an important role in aiding the diagnosis of COVID-19, as well as increasing our understanding of the disease through screening of populations for infection rates and immunity."